Mesoblast (MESO) Cash from Operations Growth (5y) (2021 - 2023)

Mesoblast (MESO) Cash from Operations Growth (5y) (2021 - 2023) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,981.90 Bn 66,981.62 Bn -
2 Nanobiotix 1,930.48 Bn 1,930.42 Bn -
3 Akari Therapeutics 1,071.19 Bn 1,071.19 Bn -
4 BeOne Medicines 468.55 Bn 463.76 Bn 1.35 Bn
5 Vertex Pharmaceuticals 123.04 Bn 115.79 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.31 Bn 61.56 Bn 3.31 Bn
7 Belite Bio 63.40 Bn 63.40 Bn -
8 Argenx Se 55.78 Bn 50.60 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.67 Bn 34.66 Bn 959.66 Mn
10 Mesoblast 18.99 Bn 18.86 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2023 4.21%
Mar 31, 2023 3.68%
Dec 31, 2022 -2.05%
Sep 30, 2022 6.84%
Jun 30, 2022 9.93%
Mar 31, 2022 9.63%
Dec 31, 2021 6.53%
Sep 30, 2021 2.66%
Jun 30, 2021 -0.90%
Mar 31, 2021 -2.12%